Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 6/20 | 0.72 |
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 6/20 | 0.59 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17681393 | 0.85 | CYP2C9 (0.70) | CYP2C9MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL15452447 | 0.79 | CYP3A4 (0.84) | CYP2C9MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL17689204 | 0.79 | CYP2C9 (0.80) | CYP2C9MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL20014197 | 0.77 | CYP2C9 (0.75) | CYP2C9MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL28672666 | 0.76 | CYP2C9 (0.68) | CYP2C9MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL22173221 | 0.75 | MAPT (0.68) | CYP2C9MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL13312263 | 0.75 | CYP2C9 (0.73) | CYP2C9MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL1901619 | 0.74 | DHODH (0.90) | CYP2C9MAPTALDH1A1KMT2ALMNA | |
| SCHEMBL14970875 | 0.74 | CYP3A4 (1.00) | CYP2C9MAPTALDH1A1L3MBTL1KMT2A | |
| SCHEMBL12488535 | 0.74 | MCL1 (1.00) | MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10350225-B1 | Small molecule inhibitors of influenza A RNA-dependent RNA polymerase | NANT HOLDINGS IP, LLC (US) | 2019-07-16 | — | — | US | disclosed |
| US-9315464-B1 | Small molecule inhibitors of influenza A RNA-dependent RNA polymerase | NANT HOLDINGS IP, LLC (US) | 2016-04-19 | — | — | US | disclosed |
| US-9315464-B1 | Small molecule inhibitors of influenza A RNA-dependent RNA polymerase | NANT HOLDINGS IP, LLC (US) | 2016-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10350225-B1 | Small molecule inhibitors of influenza A RNA-dependent RNA polymerase | RNGTT, MED23, MED25 | CYP2C9 3950/4885MAPT 2791/4885ALDH1A1 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.